Durham biotech follows billion-dollar Novartis deal with $50M offering


A gene editing firm has added $50 million to its coffers shortly after landing a significant development agreement with a global pharmaceutical company.

Previous Live Oak Bank adds Dallas office to expand small business lending
Next Biotech champion, QB3 leader Reg Kelly to retire